Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Assess the comparative efficacy of anifrolumab 300 mg versus belimumab 10 mg/kg in adults with moderate-to-severe systemic lupus erythematosus (SLE) receiving standard therapy. Patients and methods: Population-adjusted simulated treatment comparisons (primary analyses) and matching-adjusted indirect comparisons (supporting analyses) were conducted using individual patient data from TULIP-1/TULIP-2 and summary-level data from BLISS-52/BLISS-76. Results: Compared with belimumab-treated patients, anifrolumab-treated patients were more than twice as likely to achieve a reduction of four or more points in SLE Disease Activity Index 2000 score (simulated treatment comparison odds ratio: 2.47; 95% CI: 1.16–5.25) and SLE Responder Index-4 response (odds ratio: 2.61; 95% CI: 1.22–5.58) at 52 weeks. Conclusion: Patients with moderate-to-severe SLE are more likely to achieve an improvement in disease activity with anifrolumab than with belimumab.
Formats available
You can view the full content in the following formats:
Supplementary Material
File (supplementary materials (1).docx)
- Download
- 277.04 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Barber MRW, Drenkard C, Falasinnu T et al. Global epidemiology of systemic lupus erythematosus. Nat. Rev. Rheumatol. 17(9), 515–532 (2021).
2.
Justiz Vaillant AA, Goyal A, Bansal P, Varacallo M. Systemic Lupus Erythematosus. StatPearls Publishing, FL, USA (2021).
3.
Crow MK. Type I interferon in the pathogenesis of lupus. J. Immunol. 192(12), 5459–5468 (2014).
4.
Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu. Rev. Pathol. 14, 369–393 (2019).
5.
Mai L, Asaduzzaman A, Noamani B et al. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res. Ther. 23(1), 29 (2021).
6.
Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci. Med. 6(1), e000270 (2019).
7.
Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci. Med. 6(1), e000310 (2019).
8.
Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78(6), 736–745 (2019).
9.
van Vollenhoven RF, Mosca M, Bertsias G et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73(6), 958–967 (2014).
10.
Bruce IN, O’Keeffe AG, Farewell V et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann. Rheum. Dis. 74(9), 1706–1713 (2015).
11.
Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 393(10188), 2332–2343 (2019).
12.
Segura BT, Bernstein BS, McDonnell T et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology (Oxford) 59(3), 524–533 (2020).
13.
Glaxo SmithKline. Benlysta US prescribing information (2021). https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF
14.
European Medicines Agency. Benlysta: summary of product characteristics. www.ema.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf
15.
Levy RA, Gonzalez-Rivera T, Khamashta M et al. 10 Years of belimumab experience: what have we learnt? Lupus 30(11), 1705–1721 (2021).
16.
Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63(12), 3918–3930 (2011).
•• Pivotal phase III publication of the primary comparator and source of belimumab data for the analyses.
17.
Iaccarino L, Bettio S, Reggia R et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 69(1), 115–123 (2017).
18.
Navarra SV, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767), 721–731 (2011).
•• Pivotal phase III publication of the primary comparator and source of belimumab data for the analyses.
19.
Stohl W, Schwarting A, Okada M et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 69(5), 1016–1027 (2017).
20.
van Vollenhoven RF, Navarra SV, Levy RA et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a phase III study extension. Rheumatology (Oxford) 59(2), 281–291 (2020).
21.
van Vollenhoven RF, Petri M, Wallace DJ et al. Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials. Arthritis Rheumatol. 68(9), 2184–2192 (2016).
•• Pivotal pooled analysis of the primary comparator phase III data and source of belimumab data for the sensitivity analyses.
22.
Von Kempis J, Duetsch S, Reuschling N et al. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med. Wkly 149, w20022 (2019).
23.
Tanaka Y, Bae SC, Bass D et al. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open 7(2), e001629 (2021).
24.
Wallace DJ, Ginzler EM, Merrill JT et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 71(7), 1125–1134 (2019).
25.
Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs 7(2), 428–439 (2015).
26.
Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod. Rheumatol. 31(1), 1–12 (2021).
27.
US Food and Drug Administration. Saphnelo US prescribing information (2021). www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf
28.
AstraZeneca. Saphnelo approved in Japan for systemic lupus erythematosus (2021). www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-japan-for-sle.html
29.
AstraZeneca. Saphnelo recommended for approval in the EU by CHMP for the treatment of patients with systemic lupus erythematosus (2021). www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-recommended-for-eu-approval-for-sle.html
30.
AstraZeneca. Saphnelo approved in the EU for thetreatment of moderate to severe systemic lupus erythematosus (2022). www.astrazeneca.com/media-centre/press-releases/2022/saphnelo-approved-in-eu-for-sle.html
31.
Furie R, Morand E, Bruce IN et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1(4), E208–E219 (2019).
•• Pivotal phase III publication of the anifrolumab efficacy data used for the analyses.
32.
Morand EF, Furie R, Tanaka Y et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382(3), 211–221 (2020).
•• Pivotal phase III publication of the anifrolumab efficacy data used for the analyses.
33.
Chatham WW, Furie R, Saxena A et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study. Arthritis Rheumatol. 73(5), 816–825 (2021).
34.
Furie R, Khamashta M, Merrill JT et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69(2), 376–386 (2017).
•• Phase II publication of anifrolumab efficacy data and source of data used for the sensitivity analyses.
35.
Furie R, Morand EF, Askanase AD et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 30(8), 1254–1263 (2021).
36.
Tummala R, Abreu G, Pineda L et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci. Med. 8(1), e000464 (2021).
37.
Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4), 417–428 (2011).
38.
Phillippo DM, Dias S, Ades AE, Welton NJ. Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study. Stat. Med. 39(30), 4885–4911 (2020).
• Supports the use of simulated treatment comparisons as the base case.
39.
Arora S, Isenberg DA, Castrejon I. Measures of adult systemic lupus erythematosus: disease activity and damage. Arthritis Care Res. (Hoboken) 72(Suppl. 10), 27–46 (2020).
40.
Furie RA, Petri MA, Wallace DJ et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61(9), 1143–1151 (2009).
41.
Castrejón I, Tani C, Jolly M, Huang A, Mosca M. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin. Exp. Rheumatol. 32(85 Suppl. 5), S-85-95 (2014).
42.
Isenberg D, Sturgess J, Allen E et al. Study of flare assessment in systemic lupus erythematosus based on paper patients. Arthritis Care Res. (Hoboken) 70(1), 98–103 (2018).
43.
Phillippo DM, Ades T, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE (2016). https://research-information.bris.ac.uk/en/publications/nice-dsu-technical-support-document-18-methods-for-population-adj
• Provides the methodology for conducting indirect treatment comparisons.
44.
Stohl W, Schwarting A, Okada M et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 69(5), 1016–1027 (2017).
45.
Zhang F, Bae SC, Bass D et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann. Rheum. Dis. 77(3), 355–363 (2018).
46.
Wallace DJ, Kalunian KC, Petri MA et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM™, a phase IIb study. Arthritis Rheum. 62(S10), S605 (2010).
47.
Parker B, Bruce IN. Clinical markers, metrics, indices, and clinical trials. In: Dubois’ Lupus Erythematosus and Related Syndromes. Wallace DJ, Hahn B (Eds). Elsevier, Amsterdam, The Netherlands (2019).
48.
Ohmura K. Which is the best SLE activity index for clinical trials? Mod. Rheumatol. 31(1), 20–28 (2021).
49.
National Institute for Heath and Care Excellence Decision Support Unit. Population-adjusted indirect comparisons (MAIC and STC). https://nicedsu.sites.sheffield.ac.uk/tsds/population-adjusted-indirect-comparisons-maic-and-stc
50.
Ivanescu C, Skaltsa K, Kráľ P. Acceptance of population-adjusted indirect treatment comparison methods in NICE assessments. Value Health 20, A399–811 (2017).
51.
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200–211 (2018).
52.
Taraborelli M, Cavazzana I, Martinazzi N et al. Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. Lupus 26(11), 1197–1204 (2017).
53.
Urowitz MB, Gladman DD, Ibanez D et al. Effect of disease activity on organ damage progression in systemic lupus erythematosus: University of Toronto lupus clinic cohort. J. Rheumatol. 48(1), 67–73 (2021).
54.
Furie R, Morand EF, Bruce IN et al. What does it mean to be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment responder? Post hoc analysis of two phase III trials. Arthritis Rheumatol. 73(11), 2059–2068 (2021).
55.
van Vollenhoven RF, Petri MA, Cervera R et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71(8), 1343–1349 (2012).
Information & Authors
Information
Published In
Pages: 765 - 777
PubMed: 35546484
Copyright
© 2022 The Authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 25 February 2022
Accepted: 22 April 2022
Published online: 12 May 2022
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. (2022) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2022-0040
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Marco U. Martinez-Martinez, Paul J. Tejada-Llacsa, Larry J Prokop, Cynthia S. Crowson, M. Hassan Murad, Alí Duarte-García, Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis, Seminars in Arthritis and Rheumatism, 10.1016/j.semarthrit.2026.153022, 79, (153022), (2026).
- Kai Wai Lee, Becky Hooper, Jason Steenkamp, Ian N Bruce, Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab, Zeitschrift für Rheumatologie, 10.1007/s00393-026-01838-w, (2026).
- Yi Liu, Ling Xiang, Rui-Juan Cheng, Shu-Yue Pan, Advances in understanding the Th17/Treg balance in systemic lupus erythematosus: implications for treatment and management, Frontiers in Immunology, 10.3389/fimmu.2026.1795760, 17, (2026).
- Hesham Almomani, Ahmad Al-Momani, Marya Al-Momani, A Comprehensive Synthesis of Healthcare Leadership and Continuous Improvement, Evaluating Healthcare Leadership (HCL) Effectiveness: A Comprehensive Approach for Organizational Success, 10.4018/979-8-3373-2225-4.ch003, (25-38), (2025).
- Ryota Sato, Masaru Shimizu, Yuya Kondo, Kazushi Maruo, Yuki Kuroda, Hiroshi Ebe, Mizuki Yagishita, Naoto Umeda, Seiji Mogi, Ayako Ohyama, Ayako Kitada, Saori Abe, Hiromitsu Asashima, Haruka Miki, Hiroto Tsuboi, Isao Matsumoto, Real-world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reduction, Immunological Medicine, 10.1080/25785826.2025.2528296, 48, 4, (371-380), (2025).
- E. A. Pyadushkina, A. M. Lila, E. E. Yagnenkova, V. I. Ignatyeva, E. V. Derkach, New possibilities for the treatment of systemic lupus erythematosus. How much does the effect cost?, Modern Rheumatology Journal, 10.14412/1996-7012-2025-1-35-43, 19, 1, (35-43), (2025).
- Mochamad Rangga Alif Dharmawan, Maftuchah Rochmanti, undefined Awalia, Citrawati Dyah Kencono Wungu, Systematic Review and Meta-Analysis of the Efficacy and Safety Profile of Belimumab in Combination with Standard Therapy for Adults with Systemic Lupus Erythematosus, Current Internal Medicine Research and Practice Surabaya Journal, 10.20473/cimrj.v6i1.66383, 6, 1, (54-64), (2025).
- Alexander Blagov, Nikolay Orekhov, Alexey Churov, Irina Starodubtseva, Dmitry Beloyartsev, Tatiana Kovyanova, Vasily Sukhorukov, Alexander Orekhov, Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review, Antibody Therapeutics, 10.1093/abt/tbae033, 8, 1, (47-55), (2024).
- Alessio Mylonas, Neurological Impact of Type I Interferon Dysregulation, Rare Neurodegenerative Disorders - New Insights [Working Title], 10.5772/intechopen.1006023, (2024).
- Aleksandra Fijałkowska, Joanna Wojtania, Anna Woźniacka, Ewa Robak, Psoriasis and Lupus Erythematosus—Similarities and Differences between Two Autoimmune Diseases, Journal of Clinical Medicine, 10.3390/jcm13154361, 13, 15, (4361), (2024).
- See more